Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial

Chien-Te Lee, Chin-Chan Lee, Ming-Ju Wu, Yi-Wen Chiu, Jyh-Gang Leu, Ming-Shiou Wu, Yu-Sen Peng, Mai-Szu Wu, Der-Cherng Tarng, Chien-Te Lee, Chin-Chan Lee, Ming-Ju Wu, Yi-Wen Chiu, Jyh-Gang Leu, Ming-Shiou Wu, Yu-Sen Peng, Mai-Szu Wu, Der-Cherng Tarng

Abstract

Background: We explored the long-term safety and efficacy of ferric citrate in hemodialysis patients in Taiwan, and further evaluated the iron repletion effect and change of iron parameters by different baseline groups.

Methods: This was a 12-month, Phase IV, multicenter, open-label study. The initial dose of ferric citrate was administered by patients' clinical condition and further adjusted to maintain serum phosphorus at 3.5-5.5 mg/dL. The primary endpoint was to assess the safety profiles of ferric citrate. The secondary endpoints were to evaluate the efficacy by the time-course changes and the number of subjects who achieved the target range of serum phosphorus.

Results: A total of 202 patients were enrolled. No apparent or unexpected safety concerns were observed. The most common treatment-emergent adverse events were gastrointestinal-related with discolored feces (41.6%). Serum phosphorus was well controlled, with a mean dose of 3.35±1.49 g/day, ranging from 1.5 to 6.0 g/day. Iron parameters were significantly improved. The change from baseline of ferritin and TSAT were 227.17 ng/mL and 7.53%, respectively (p-trend<0.001), and the increase started to slow down after 3-6 months of treatment. In addition, the increase trend was found only in patients with lower baseline level of ferritin (≤500 ng/mL) and TSAT (<30%).

Conclusions: Ferric citrate is an effective phosphate binder with favorable safety profile in ESRD patients. The iron-repletion by ferric citrate is effective, and the increase is limited in patients with a higher baseline. In addition to controlling hyperphosphatemia, ferric citrate also shows additional benefits in the treatment of renal anemia.

Clinical trial registration: ClinicalTrials.gov ID: NCT03256838; 12/04/2017.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow diagram of subjects by…
Fig 1. Flow diagram of subjects by completion status.
Fig 2
Fig 2
The impact of ferric citrate treatment on the changes of (A) serum phosphorus, (B) hemoglobin and serum iron, (C) TSAT, ferritin, and TIBC and (D) iPTH and calcium from M0 to EOT. Abbreviations: TSAT, transferrin saturation; TIBC, total iron binding capacity; iPTH, intact parathyroid hormone; M0, baseline; EOT, end-of-treatment. The values were expressed as mean and standard error (SE).
Fig 3
Fig 3
Changes in (A) ferritin and (B) TSAT from M0 to EOT according to different baselines of ferritin (500 ng/mL) and TSAT (

References

    1. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease. Perm J. 2016;20(3):15–127. doi: 10.7812/TPP/15-127
    1. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al.. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–1127. doi: 10.1001/jama.2011.308
    1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218. doi: 10.1097/01.ASN.0000133041.27682.A2
    1. Waheed AA, Pedraza F, Lenz O, Isakova T. Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant. 2013;28(12):2961–2968. doi: 10.1093/ndt/gft244
    1. Huml AM, Sullivan CM, Leon JB, Sehgal AR. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Ren Fail. 2012;34(10):1258–1263. doi: 10.3109/0886022X.2012.718724
    1. Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol. 2015;39(6):767–771. doi: 10.1097/PAS.0000000000000385
    1. Nastou D, Fernandez-Fernandez B, Elewa U, Gonzalez-Espinoza L, Gonzalez-Parra E, Sanchez-Nino MD, et al.. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74(8):863–877. doi: 10.1007/s40265-014-0224-6
    1. McCullough PA, Uhlig K, Neylan JF, Pergola PE, Fishbane S. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. Am J Cardiol. 2018;122(4):683–688. doi: 10.1016/j.amjcard.2018.04.062
    1. Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, et al.. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrol Dial Transplant. 2019;34(7):1115–1124. doi: 10.1093/ndt/gfy318
    1. Pergola PE, Fishbane S, LeWinter RD, Neylan JF, Uhlig K, Block GA, et al.. Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia. Am J Hematol. 2018;93(6):E154–E156. doi: 10.1002/ajh.25088
    1. Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S. Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One. 2017;12(11):e0188712. doi: 10.1371/journal.pone.0188712
    1. Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ, et al.. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol. 2018;22(4):789–796. doi: 10.1007/s10157-017-1510-x
    1. Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, et al.. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. J Am Soc Nephrol. 2017;28(6):1851–1858. doi: 10.1681/ASN.2016101053
    1. Komatsu N, Arita K, Mitsui H, Nemoto T, Hanaki K. Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. Int J Hematol. 2021;114(1):8–17. doi: 10.1007/s12185-021-03123-9
    1. Pergola PE, Belo D, Crawford P, Moustafa M, Luo W, Goldfarb-Rumyantzev A, et al.. Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease. Am J Nephrol. 2021;52(7):572–581. doi: 10.1159/000516012
    1. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al.. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26(2):493–503. doi: 10.1681/ASN.2014020212
    1. Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, et al.. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs R D. 2015;15(3):271–279. doi: 10.1007/s40268-015-0103-y
    1. Yoshida T, Morimoto K, Kaburagi N, Fujino T, Takemitsu TY, Yamashita N, et al.. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients. Int Urol Nephrol. 2021. doi: 10.1007/s11255-021-02952-1
    1. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al.. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162–168. doi: 10.1038/ki.2014.275
    1. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al.. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532–1542. doi: 10.1016/S0140-6736(09)60502-X
    1. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9(2):260–267. doi: 10.1093/ckj/sfv142
    1. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis. 2018;71(3):423–435. doi: 10.1053/j.ajkd.2017.09.026
    1. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al.. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA. 2015;314(19):2062–2068. doi: 10.1001/jama.2015.15572
    1. Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, et al.. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing. Clinical journal of the American Society of Nephrology: CJASN. 2015;10(10):1814–1821. doi: 10.2215/CJN.02600315
    1. Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney international supplements. 2015;5(1):23–32. doi: 10.1038/kisup.2015.6
    1. Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, et al.. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. Journal of nephrology. 2015;28(1):105–113. doi: 10.1007/s40620-014-0108-6
    1. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al.. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2014;24(4):261–267. doi: 10.1053/j.jrn.2014.03.006
    1. Hung SC, Kuo KL, Tarng DC, Hsu CC, Wu MS, Huang TP. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology (Carlton, Vic). 2014;19(12):735–739. doi: 10.1111/nep.12332
    1. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348–359. doi: 10.1056/NEJMra1004967
    1. Szczech L. Chronic kidney disease: Association between ESA use and stroke in patients with CKD. Nat Rev Nephrol. 2011;7(7):365–366. doi: 10.1038/nrneph.2011.70
    1. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al.. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80(3):288–294. doi: 10.1038/ki.2011.49
    1. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA, et al.. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol. 2007;578(Pt 1):309–314. doi: 10.1113/jphysiol.2006.122689
    1. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost. 2010;36(5):537–549. doi: 10.1055/s-0030-1255448
    1. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al.. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;(12):CD010590. doi: 10.1002/14651858.CD010590.pub2
    1. Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008;42(12):1865–1870. doi: 10.1345/aph.1L231
    1. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–6380. doi: 10.1158/1078-0432.CCR-10-2577
    1. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al.. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924. doi: 10.1001/jama.299.8.914
    1. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29(2):255–259. doi: 10.1093/ndt/gft269
    1. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol. 2008;19(9):1817–1826. doi: 10.1681/ASN.2007101084
    1. Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, et al.. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017;32(8):1330–1338. doi: 10.1093/ndt/gfw242

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner